Abbott Laboratories (ABT) said Monday new results from a trial showed that the TriClip transcatheter edge-to-edge repair system to treat leaky heart valves provided "substantial and sustained improvements" in the severity of the condition after two years.

The data also showed that that the device significantly reduced the rate of heart failure hospitalizations and improved the quality of life of patients, the company said.

Abbott shares were slightly higher in recent trading.

Price: 131.81, Change: +0.99, Percent Change: +0.76